News

Article

Levodopa-Enhancing Activity Observed With Bezisterim in Phase 2A Study of Parkinson Disease

Author(s):

After 28 days of treatment, bezisterim showed pronounced effects on measures of the Non-Motor Symptom Scale, as well as greater achievement of ON time than levodopa alone.

Joseph Palumbo, chief medical officer at BioVie

Joseph Palumbo

Recently announced data from a phase 2a study showed that as an adjunctive therapy to levodopa, bezisterim (BioVie) may hold promise in ameliorating specific non-motor symptoms of Parkinson disease (PD), particularly issues with fatigue and restlessness of the legs. Patients aged less than 70 years treated with bezisterim and carbidopa/levodopa (C/L) experienced the greatest improvement with treatment in comparison to the overall cohort, which featured patients aged up to 80 years old.1,2

The trial featured 46 patients with PD who had a history of motor fluctuations, bradykinesia, and motor response to levodopa who were randomly assigned 1:1 to either bezisterim 20 mg twice a day (BID) with immediate-release (IR) C/L or placebo plus IR C/L for 27 days. Bezisterim is an oral, blood-brain barrier-permeable molecule that binds extracellular signal-regulated kinase (ERK) and has anti-inflammatory and insulin-sensitizing activities via inhibition of inflammatory (but not homeostatic) ERK and NF-kB activation and tumor necrosis factor-alpha signaling.

In the bezisterim + C/L group, investigators observed changes of –18.6 and –15.6 on Movement Disorder Society-Unified Parkinson’s Disease Rating Scale-Part III at hours 2 and 3, respectively, in comparison to –16.2 and –12.8 with levodopa alone. These improvements were even greater among those aged less than 70 years old (bezisterim + levodopa: –20.2 and –17.0; levodopa: –16.3 and –12.3). For context, around 50% of the total patient population was less than 70 years old.

Additional findings showed that more bezisterim-levodopa combination treated patients who experienced an OFF state at baseline experienced a morning ON state prior to dosing on day 28. All told, 6 of the 20 (30%) of those on the combination approach had ON state vs 0 of 19 placebo-treated patients (0%). This difference was considered statistically significant (P = .02).

Within the bezisterim group, patients saw a –2.4 change (improvement) in Non-Motor Symptom Scale (NMSS) Sleep/Fatigue domain score, in comparison with those on placebo, who worsened by 1.0 points (P = .0159; cohen’s d = –0.5). Notably, sleep/fatigue domain improvements significantly correlated with motor score improvements (r = .51; P = .0259).

"These full dataset findings suggest that bezisterim as adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson Disease, particularly in sleep/fatigue and restlessness of the legs,” Joseph Palumbo, chief medical officer at BioVie, said in a statement.1 "These findings extend previously reported improvement in motor symptoms with bezisterim and demonstrate potential intrinsic and levodopa-enhancing activity of bezisterim that is consistent with data from animal models and support further clinical investigation of bezisterim in late-phase trials."

READ MORE: FDA Grants Regenerative Medicine Advanced Therapy Designation to Parkinson Cell Therapy Candidate Bemdaneprocel

Results from the study showed significant improvement in fatigue/lack of energy (Q4), as well as urge to move legs/restlessness in legs (Q6) among bezisterim-treated patients but not placebo. Among all patients, those on bezisterim showed changes of –0.87 (90% CI, –1.24 to –0.50; P = .0005; Cohen’s d = –0.26) for fatigue/lack of energy vs –0.39 (90% CI, –79 to –0.02) for those on placebo. In a separate group of patients with symptoms at baseline, the bezisterim group (n = 8) showed changes of –2.25 (90% CI, –3.73 to –0.77; P = .0267; Cohen’s d = –0.15) in comparison with changes of –1.86 (90% CI, –3.44 to –0.27; P = .0759) for placebo.

Using NMSS to assess urge to move legs/restlessness in legs, patients in the overall cohort showed score changes of –0.89 (90% CI, –1.81 to 0.03; P = .01215) with bezisterim whereas those on placebo saw worsening of 0.99 (90% CI, –0.01 to 1.99; P = .1141). For those with symptoms at baseline, bezisterim-treated patients had changes of –2.91 (90% CI, –4.31 to –1.50; P = .0036; Cohen’s d = –0.81) vs placebo, which had changes of –0.71 (90% CI, –2.48 to 1.05; P = .5141).

Bezisterim is also being currently assessed as a therapeutic for patients with Alzheimer disease (AD). In a recently presented randomized, placebo-controlled trial, treatment with the agent demonstrated potential to restore homeostasis and decrease biological aging in a small per-protocol sample of patients. All told bezisterim-treated patients displayed –4.77 years advantage on the Inflammation Age Clock (P = .022), –5.0 years advantage on the Hannum Age Clock (P = .006), –1.92 years advantage on the GrimAge Clock (P = .068), and –3.71 years on the PhenoAge Clock (P = .081). In addition, this group had a –3.68-year advantage on SkinBlood Clock (P = .017), a previously published finding.

Overall, decreased age acceleration found in bezisterim was correlated with improvements in neurologic assessments, including CDR-SB (Pearson r = 0.413; P = .099), ADAS-Cog12 (Pearson r = .455; P = .067), Mini-Mental State Exam (MMSE; Pearson r = –0.580; P = .015), Alzheimer’s Disease Assessment Scale (ADCOMS; Pearson r = .469; P = .058), and Alzheimer’s Disease Composite Score-Clinical Global Impression of Change (ADCS-CGIC; Pearson r = .467; P = .059). In comparison, there were no correlations with neurologic assessments for placebo.3

REFERENCES
1. BioVie’s bezisterim demonstrates potential improvement in sleep/fatigue and restless leg symptoms for Parkinson’s disease patients. News release. BioVie. May 22, 2024. Accessed June 7, 2024. https://finance.yahoo.com/news/biovie-bezisterim-demonstrates-potential-improvements-120000796.html
2. Palumbo J, Reading CL, Ahlem C, et al. Improvement of motor and non-motor symptoms with bezisterim adjunctive to carbidopa/levodopa in patients with Parkinson’s disease: a phase 2a, placebo-controlled study. Presented at: World Congress on Parkinson’s Disease and Related Disorders; Lisbon, Portugal. May 19-22; 2024.
3. Reading CL, Yan J, Testa MA, et al. Clinical outcomes and biomarker findings from a randomized, placebo-controlled trial of bezisterim in subjects with mild to moderate probable Alzheimer’s disease. Presented at: 12th Annual Alzheimer’s and Parkinson’s Drug Development Summit; April 23-25; Boston, MA.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
David Shprecher, DO, MSci, FAAN
Pamela Zeilman, NP
 Esther Labib-Kiyarash, MSHA, CPHQ
Justin Martello, MD
William Ondo, MD
© 2025 MJH Life Sciences

All rights reserved.